7 completed, 2 terminated, 1 unknown. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 7, Terminated 2, Unknown 1 |
Follow Deferiprone: new trials by email Literature Review of Deferiprone trials Research Report on Deferiprone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children Deferiprone oral solution, Placebo - Beta Thalassemia Major Anemia, Iron Overload | Phase 4 | Completed | Chiesi Canada Corp | 64 | 2018-11-09 | 2024-03-15 |
| Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Deferiprone - Iron Overload, Sickle Cell Disease | Phase 4 | Terminated | ApoPharma | 134 | 2015-05-21 | 2024-01-10 |
| Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Deferiprone, Deferoxamine - Iron Overload, Sickle Cell Disease | Phase 4 | Terminated | ApoPharma | 230 | 2014-04-17 | 2021-08-10 |
| An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment Deferiprone - Renal Impairment | Phase 4 | Completed | ApoPharma | 32 | 2013-01-01 | 2014-08-26 |
| An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers Ferriprox® - Hepatic Impairment | Phase 4 | Completed | ApoPharma | 21 | 2013-01-01 | 2014-09-10 |
| Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects Deferiprone, deferiprone matching placebo tablets, moxifloxacin - Prolonged QTc Interval | Phase 4 | Completed | ApoPharma | 50 | 2012-11-01 | 2014-11-12 |
| Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major deferiprone - Beta-Thalassemia | Phase 4 | Unknown | Royal Brompton & Harefield NHS Foundation Trust | 65 | 2004-05-01 | 2005-06-24 |
| Efficacy Study in Removing Excess Iron From the Heart Ferriprox (deferiprone), Desferal (deferoxamine) - Thalassemia Major, Hemosiderosis | Phase 4 | Completed | ApoPharma | 60 | 2002-12-01 | 2016-01-05 |
| Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major Deferoxamine and Deferiprone, Deferoxamine - Iron Overload, Cardiomyopathy | Phase 4 | Completed | Ospedale Microcitemico | 2001-12-01 | 2008-12-02 | |
| Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Deferiprone (DFP) and Deferoxamine (DFO), Deferiprone (DFP) - Beta-Thalassemia, Thalassemia Major | Phase 4 | Completed | Azienda Ospedaliera V. Cervello | 213 | 2000-09-01 | 2008-08-13 |
Iron Overload (5) · beta-Thalassemia (3) · Anemia, Sickle Cell (2) · Thalassemia (2) · Cardiomyopathies (1) · Hemochromatosis (1) · Hemosiderosis (1) · Kidney Diseases (1) · Liver Diseases (1) · Renal Insufficiency (1)
ApoPharma (6) · Azienda Ospedaliera V. Cervello (1) · Chiesi Canada Corp (1) · Ospedale Microcitemico (1) · Royal Brompton & Harefield NHS Foundation Trust (1)
Italy (4) · United States (4) · Canada (3) · Egypt (3) · Saudi Arabia (2) · United Kingdom (2) · Brazil (1) · Greece (1) · Indonesia (1) · Tunisia (1) · Turkey (Türkiye) (1)
Fernando Tricta, MD (3) · Janet Kwiatkowski, MD (2) · Antonio Piga, M.D. (1) · Caroline Fradette, PhD (1) · Maria E Lai, MD (1) · Markissia Karagiorga, M.D. (1) · Mohsen El Alfy, MD (1) · Renzo Galanello, M.D. (1) · Vassilis Ladis, M.D. (1)
PMID 18298856, PMID 19236376, PMID 34847228, PMID 36018224, PMID 37807937, PMID 37975597